All issues > Volume 44(11); 2001

Case Report

J Korean Pediatr Soc. 2001;44(11):1330-1333. Published online November 15, 2001.

A Case of Successful Danazol Therapy in Autoimmune Thrombocytopenia Associated with Systemic Lupus Erythematosus

Kyung Min KM Kim¹, Byeong Seon BS Lee¹, Young Seo YS Park¹

¹Department of Pediatrics, College of Medicine, Ulsan University, Seoul, Korea

Correspondence Young Seo YS Park ,Email: yspark@amc.seoul.kr

Abstract

Autoimmune thrombocytopenia and autoimmune hemolytic anemia occur in 10-26% of patients with systemic lupus erythematosus(SLE). These hematological manifestations may be the sole presenting sign and can precede the appearance of diagnosable SLE in 5 to 23% of cases. The conventional treatment for SLE associated with these disorders includes corticosteroid therapy and splenectomy, but autoimmune thrombocytopenia or autoimmune hemolytic anemia may be refractory to both treatments. We experienced a case of a SLE patient complicated by severe autoimmune thrombocytopenia. Therapy with intravenous immunoglobulin and corticosteroids failed. She responded to danazol and remission of thrombocytopenia(platelet >100,000/mm3) was observed 7 days after starting danazol. Danazol therapy seems to be a useful and well tolerated treatment for refractory autoimmune thrombocytopenia associated with SLE.

Keywords :Danazol, Autoimmune thrombocytopenia, Systemic lupus erythematosus